Novartis announced strong top-line data for its anti-inflammatory drug, marketed as Ilaris/ canakinumab, in reducing heart attacks on people who have survived one before. In a global phase III study called CANTOS, evaluating 10,000 patients, canakinumab (when used in combination with standard of care) was able to reduce the risk of major adverse cardiovascular (CV) events. The detailed results will be presented at the European Society of Cardiology Congress in late August. Celebrating this de
23 Jun 2017
A stroke of luck
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A stroke of luck
Novartis AG (0QLR:LON) | 0 0 0.7% | Mkt Cap: 208,186m
- Published:
23 Jun 2017 -
Author:
Kamla Singh -
Pages:
3
Novartis announced strong top-line data for its anti-inflammatory drug, marketed as Ilaris/ canakinumab, in reducing heart attacks on people who have survived one before. In a global phase III study called CANTOS, evaluating 10,000 patients, canakinumab (when used in combination with standard of care) was able to reduce the risk of major adverse cardiovascular (CV) events. The detailed results will be presented at the European Society of Cardiology Congress in late August. Celebrating this de